Pomalidomide

POMALYST®

Overview

Pomalidomide is a cancer medicine that promotes an immune response to help slow tumor growth. It is used in combination with dexamethasone to treat people with relapsed/refractory multiple myeloma who have received at least two prior medicines to treat their myeloma (including a type of medicine known as a proteasome inhibitor and lenalidomide).

SparkCures ID 5
Developed By Celgene Corporation
Brand Name Pomalyst®
Generic Name Pomalidomide
Additional Names CC-4047, Actimid
Treatment Classifications

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

SparkCures Verified Accurate, up-to-date information. Learn more


Untreated / Newly Diagnosed Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

SparkCures Verified Accurate, up-to-date information. Learn more


Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

SparkCures Verified Accurate, up-to-date information. Learn more


Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Resources

There are no resources, links or videos to display for this treatment.